^
Association details:
| Biomarker: | BCL2L1 overexpression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
BCL-Xl Expression Is Druggable Biomarker Associated with a Poor Clinical Outcome in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Published date:
11/06/2019
Excerpt:
Over-expression of BCL-XL RNA levels was associated with a shorter OS (P=0.015, HR=1.17) . Pre-clinically higher levels of Bcl-XL as determined by western blotting were found in lymphoma cell lines resistant to chemotherapy agents in vitr...
DOI:
10.1182/blood-2019-128512
